Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Drew D. Kiraly

2 papers in the library · 182 citations · publishing 2017

Papers

Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome

Translational Psychiatry March 21, 2017 Drew D. Kiraly, Sarah R. Horn, Nicholas T. van Dam et al. 182 citations

Patients with treatment-resistant depression (TRD) show elevated levels of the pro-inflammatory cytokine interleukin-6 compared to healthy controls, supporting the immune hypothesis of depression. Analysis of 41 cytokines, chemokines, and growth factors in blood samples from 26 healthy controls and 33 unmedicated TRD patients revealed a unique pattern of increased inflammatory mediators, chemokines, and colony-stimulating factors. Following a single intravenous infusion of ketamine (0.5 mg/kg), several cytokines showed transient changes, but none correlated with treatment response. Low pretreatment levels of fibroblast growth factor 2 were associated with ketamine treatment response, suggesting novel treatment targets for TRD patients with dysregulated immune functioning.

DOI: 10.1038/tp.2017.31 (opens in new tab) Full text (opens in new tab) Ketamine Major depressive disorder Treatment-resistant depression Immune system +10

Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial.

Journal of Affective Disorders August 15, 2017 James W. Murrough, Elizabeth Wade, Sehrish Sayed et al.

A combination of dextromethorphan and quinidine, given at up to 45/10 mg twice daily for 10 weeks, reduced depression scores in patients with treatment-resistant depression. Twenty patients with unipolar treatment-resistant depression enrolled; six discontinued early. Depression scores on the Montgomery-Asberg Depression Rating Scale dropped by an average of 13 points, and on the Quick Inventory of Depressive Symptomatology by nearly 6 points. Response and remission rates were 45% and 35%, respectively. No treatment-emergent suicidal thoughts, psychosis, or dissociation occurred. The open-label, proof-of-concept design limits conclusions, but results suggest the combination is tolerable and warrants larger placebo-controlled trials.

DOI: 10.1016/j.jad.2017.04.072 (opens in new tab) Full text (opens in new tab) Depression Antidepressant Dextromethorphan Glutamate +2